Moreover, co-targeting Pi3K-AKT-mTOR and MAP kinase pathways with a combination of alpelisib and trametinib provided an additive effect on the inhibition of cell viability in Ben-Men-1, IOMM-Lee and all human fresh meningiomas tested. Here, PIK3CA is linked to meningioma.